All In Biotech

Drug Trial Radar · NCT07724457

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

A Randomized Phase 2/3 Study of the Bispecific Antibody (BsAb), Glofitamab, Plus Chemoimmunotherapy in Newly Diagnosed and Relapsed Burkitt and High-Grade (Double Hit) B-Cell Lymphomas With MYC and BCL2 Rearrangements

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 271 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

271

Planned (sponsor's estimate)

Start

Jul 27, 2027

Primary completion

Nov 1, 2033

Study completion Nov 1, 2033

Sponsor

Sponsor type
NIH
First posted
Jul 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly diagnosed, that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Glofitamab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Obinutuzumab and rituximab are also monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make DNA and may kill cancer cells. Chemotherapy drugs, such as cytarabine and ifosfamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Giving glofitamab with standard of care chemotherapy may work well for the treatment of newly diagnosed, relapsed or refractory Burkitt and high grade (double hit) B- cell lymphomas.

Conditions

  • Recurrent Burkitt Lymphoma
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
  • Refractory Burkitt Lymphoma
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood and/or cerebrospinal fluid collection

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • CarboplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT scan

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IV or IT

  • DoxorubicinDrug

    Given IV

  • EtoposideDrug

    Given IV

  • GlofitamabBiological

    Given IV

  • IfosfamideDrug

    Given IV

  • Lumbar PunctureProcedure

    Undergo lumbar puncture

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • MethotrexateDrug

    Given IV or IT

  • ObinutuzumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET scan

  • PrednisoneDrug

    Given PO

  • RituximabBiological

    Given IV

  • Rituximab and Hyaluronidase HumanBiological

    Given SC

  • Survey AdministrationOther

    Ancillary studies

  • VincristineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) (cohort 1) (phase II)Time frame: from randomization to the time of documented disease progression or death due to any cause
  2. PFS (cohort 1) (phase III)Time frame: At 24 months
  3. PFS (cohort 2) (phase II)Time frame: From randomization to the time of documented disease progression or death due to any cause, up to 5 years
  4. PFS (cohort 2) (phase III)Time frame: At 24 months
  5. Overall survival (cohort 3)Time frame: At 12 months after start of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alliance for Clinical Trials in Oncology

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.